The increase in oxygen consumption caused by administration of epinephrine has been extensively studied in animals and in man. Many physiological and biochemical correlations have been made and many different hypotheses have been advanced to explain this so-called calorigenic effect, but there is still no clearly established consensus regarding the mechanism or mechanisms involved (1, 2).
The increase in oxygen consumption caused by administration of epinephrine has been extensively studied in animals and in man. Many physiological and biochemical correlations have been made and many different hypotheses have been advanced to explain this so-called calorigenic effect, but there is still no clearly established consensus regarding the mechanism or mechanisms involved (1, 2) .
In recent years it has become clear that one of the most striking metabolic effects of the catecholamines is their ability to stimulate mobilization of depot fat in the form of free fatty acids (FFA) (3) . Studies by Fritz, Davis, Holtrop, and Dundee (4) and by Eaton and Steinberg (5) have shown, moreover, that the rate of oxidation of labeled FFA by isolated skeletal muscle preparations in vitro is a function of the concentration of FFA in the medium. Similar effects of FFA concentration on FFA oxidation have been demonstrated in rat liver slices (6) and in perfused rat liver (7) . We have previously suggested, therefore, that the calorigenic action of catecholamines might be due, at least in part, to their effect in mobilizing FFA (5) .
The present clinical studies were undertaken to explore this possibility further. Because the metabolic effects of epinephrine are somewhat more complex than those of norepinephrine, in that the former actively mobilizes glucose as well as FFA, the present studies were done primarily with norepinephrine. It is shown that infusion of norepinephrine increases the rate of oxygen consumption in man and that this is accompanied by an increase in turnover of plasma FFA and an increase in rate of conversion of labeled plasma FFA to respiratory C1402. All of these effects of norepinephrine are abolished or radically reduced when the patient has first been given an intravenous dose of pronethalol [2-isopropylamino-1-(2-naphthyl)ethanol hydrochloride], a drug that inhibits catecholamine stimulation of adrenergic , 8-receptors (8, 9) and that prevents the FFA mobilization induced by catecholamines (10) .1 A preliminary report of these findings has been made (11) . Methods
The subjects studied were young, adult, normal, control volunteers on regular ward diets, with their total caloric intake adjusted to maintain constant body weight. Metabolic studies were all done after a 12-to 16-hour fast, and subjects remained at rest in bed on the mornings of studies. Indwelling plastic catheters were placed in an antecubital vein of each arm after the skin had been anesthetized with Xylocaine (2-diethylamino-2',6'-acetoxylidide). A slow drip of 0.85% NaCl was maintained to keep the catheters open. The subj ects were then taken to the metabolic chamber in a wheel chair. The construction and operation of the metabolic chamber have been fully described by Buskirk, Thompson, Moore, and Whedon (12) . At least 30 minutes was allowed to establish stable control values for rate of oxygen consumption. Blood samples were drawn from one arm through a 3-way stopcock and delivered into a chilled tube containing heparin. Infusions of drugs, or labeled palmitate, or both, were given into the opposite arm with Bowman finger pumps.
Plasma FFA were determined by Dole's method (13) using isobctane (2,2,4-trimethylpentane) in place of hep- 1 Since these studies were completed, the Research Department of Imperial Chemical Industries, Ltd., Macclesfield, England, manufacturers of pronethalol (Alderlin), has found that mice on chronic high dosage show a significant incidence of locally malignant lymphosarcomata of the thymus gland. Further use of the drug in clinical investigation should probably await thorough eva'uation of these preliminary findings. tane. Blood glucose was measured enzymatically by the glucose oxidase method described by Keston (14) . Reagents (Glucostat) were obtained commercially.2 Plasma lactate levels were determined enzymatically (15) .
Plasma FFA turnover was determined by using a constant intravenous infusion of palmitate-1-C'4. The basis for this method has been fully discussed by Armstrong and associates (16 tracting by Dole's method, re-extracting the F-FA from the isooctane layer into alcoholic KOH, acidifying the latter, and finally re-extracting the FFA into isooctane. The isooctane was dried in a counting vial under a stream of N2, the residue was redissolved in toluene containing 0.5% 2,5-diphenyloxazole, and radioactivity was assayed in a Packard Tri-Carb liquid scintillation spectrometer. In several experiments the lipids in the final isodctane extract were fractionated on silicic acid columns (17) . No significant amounts of radioactivity were recovered with the phospholipid fraction.
For measurement of C1402 production, a measured fraction of the gas stream from the metabolic chamber was diverted and collected in 4-to 5-minute periods in Douglas bags. The gas from these bags was slowly pulled through a gas-flow meter and delivered through a sintered glass diffuser into a column of NaOH. A Ba(OH)2 trap connected in series showed that collection of CO, was complete. Three-ml samples of the NaOH were added to 1 g of fluorescence-grade anthracene,5 and 4 Packard Instrument Co., La Grange, Ill. 5 Distillation Products, Inc., Rochester, N. Y. radioactivity was assayed in the liquid scintillation spectrometer ( 18) . Pronethalol (Alderlin) was generously donated.0 Norepinephrine (Levophed) was diluted in 0.85%o NaCl to a final concentration of 6.6 ,ug per ml (expressed as the base).
Results
The changes in blood pressure, pulse rate, FFA concentration, and oxygen consumption produced 6 Ayerst Laboratories, New York, N. Y.
by intravenous infusion of norepinephrine are summarized in Tables I and II. In Table lI 16 11 Control valuesi 16 9 Before pronethalol Control values R.B., 13 18 M. 35, 21 14 86. Tables I and II) . The responses ranged from + 11 to + 397o.
FFA levels and turnover. Basal FFA levels in the plasma, determined after the subjects were in position in the metabolic chamber and just before the norepinephrine infusion was started, were 0.58 ± 0.19 uEq per ml. At the time when the maximal response in oxygen consumption was reached, FFA levels had risen to 1.28 ± 0.27 uEq per ml, an increase of 127 ± 57%o over basal values.
In seven subjects FFA turnover was determined before and during norepinephrine treatment by using a continuous intravenous infusion of palmitate-1-C14. In every case norepinephrine caused an increase in turnover, but the response was variable, ranging from 11 to 154%o
above control values with a mean rise of 74 ± 53%o (Tables I and II) . The percentage increase in FFA turnover was greater than the percentage increase in oxygen consumption in six of the seven cases. The mean percentage increase in FFA turnover for the seven cases studied (74%) was more than three times the mean percentage increase in oxygen consumption (24%o).
Pulse and blood pressure. Within a minute or two after the infusion was started, blood pressure rose and pulse rate decreased. The bradycardia, presumably a reflex response to the rise in blood pressure, was generally most marked during the first 5 minutes, the heart rate returning toward control values when the infusion was continued at a constant rate. At the time when the maximal changes in oxygen consumption were observed, the mean decrease in pulse rate was 9 beats per minute. At that time systolic blood pressure had risen 36 mm and diastolic 26 nmm of Hg above control levels.
A few patients reported headache or pounding in the head, and a few noted difficulty in "getting a deep breath" during the first few minutes of the infusion. These symptoms were transient, and most patients had no discomfort during the latter part of the infusion period. There were no other adverse reactions.
Because fear and anxiety can cause elevations of FFA and might lead to increases in oxygen consumption, we restudied patient C. H., a somewhat apprehensive individual, following the standard protocol but infusing only 0.85%o sodium chloride. The usual control blood samples were taken, the Bowman pump was started, and the recording technician was told to mark "norepinephrine started" at that time. There were no changes of any significance in plasma FFA level or oxygen consumption (Table I, Effects of pronethalol. In six experiments pronethalol was given intravenously (75 to 100 mg over a 10-minute period) after the rate of oxygen consumption had returned to control levels following discontinuing of the control norepinephrine infusion. A second infusion of norepinephrine was then given at the same dosage rate used in the first infusion, and the same parameters of response were measured (Tables II and III) .
Pronethalol treatment did not materially alter the changes in pulse rate and blood pressure induced by norepinephrine. On the other hand, the rises in plasma FFA levels and the rises in rate of oxygen consumption were radically reduced or entirely abolished. The data from a representative experiment (Case B.L., I, in Table  II) are presented graphically in Figure 1 . The rise in blood pressure and the slowing of the pulse rate were essentially the same with and without prior pronethalol treatment Table II ), a 23-year-old male weighing 66.1 kg. Arrows indicate points at which norepinephrine infusion was begun (START NE) and ended (STOP NE). Pronethalol, 100 mg, was given intravenously over the 10-minute period indicated. Norepinephrine was infused at a rate of 16 ,ug per minute during each of the three experimental periods, one before and the other two after pronethalol administration. tion persisted after the end of the infusion, and the return to basal levels was rather slow. In this study two infusions of norepinephrine were given after the administration of pronethalol. The rate of oxygen consumption, instead of rising, actually fell during these infusions and then showed some "rebound" above basal levels when the infusion was stopped. If the oxygen consumption during and after the norepinephrine infusion is integrated, the net change is close to zero.
In Tables II and III the responses are shown at the time of the peak in oxygen consumption during the control infusion of norepinphrine and then at the corresponding time during the postpronethalol infusion of norepinephrine. The "rebound" is not shown, but was noted in all cases and was in no case greater in relative magnitude than that shown in Figure 1 . Plasma FFA levels fell during the postpronethalol infusion of norepinephrine in four of the six experiments. The levels then rose to values equal to or greater than control values when the norepinephrine infusion was stopped.
In five studies the changes in FFA turnover induced by norepinephrine were measured before and after administration of the blocker. Whereas the turnover was increased by norepinephrine given before pronethalol treatment, it was either not changed or actually fell when norepinephrine was given after pronethalol treatment.
These effects of pronethalol on the responses to norepinephrine are summarized in Table IV. Changes in blood glucose and serum lactate.
In four studies the blood glucose level was determined at 5-to 10-minute intervals. Control values were 83, 86, 92, and 92 mg per 100 ml; peak values, reached just at the end, or 5 to 10 (19) (20) (21) (22) (23) . We are aware of only one previous report of positive results in man (24) , however, although several investigators have reported no effect of norepinephrine on oxygen consumption in man (25) (26) (27) (28) . The calorigenic action of norepinephrine has been found to be smaller than that of epinephrine in rats (19) , guinea pigs (20) , and rabbits (21) , and this is our experience in recent clinical studies (29) . The results presented above, however, establish that under the conditions used norepinephrine has a significant calorigenic action in man.
With the rise in oxygen consumption there was a marked increase in the rate of fat mobilization manifested by an increase in concentration and rate of turnover of plasma FFA. Plasma FFA concentrations rose on the average by 127% and calculated turnover by 74%. Conversion of palmitate-1-C'4 to C1402 was simultaneously increased.
The question arises as to whether the rise in oxygen consumption, directly or indirectly, was a consequence of the FFA mobilization induced by norepinephrine. Pilkington, Lowe, Robinson, and Titterington (10) showed that pronethalol, a rather specific inhibitor of adrenergic receptors of the /8 class (8, 9), blocked the FFA-mobilizing action of epinephrine. As shown here, the FFAmobilizing action of norepinephrine was similarly blocked. The associated rise in oxygen consump-tion, the calorigenic action, was also blocked. Preliminary studies have shown that the calorigenic action of epinephrine in man is likewise blocked by pronethalol (29) . The concomitance of the two effects and the fact that both are blocked by pronethalol is compatible with, but does not establish, a cause and effect relationship between the FFA-mobilizing action and the calorigenic action of catecholamines. The catecholamines have many physiological activities in addition to their fat-mobilizing activity. The possibility that other catecholamine effects are more relevant to the calorigenic action and that these are simultaneously inhibited by pronethalol cannot be ruled out. At least, the fat-mobilizing action of the hormones and their activities relevant to the calorigenic effect are both blocked by pronethalol, and the receptors involved thus fall operationally into the category of f8 receptors.
The degree to which FFA are diluted in pools of nonradioactive fatty acids after leaving the plasma and before being oxidized is not known. It is therefore not possible to draw firm conclusions regarding the rate at which fatty acids are being oxidized from data of the kind presented here. A minimal figure can be calculated by assuming no dilution, and as shown in Table III (40) . The increment in oxygen consumption may partly reflect the energy used for the breakdown and resynthesis of triglycerides within the adipose tissue, as proposed by Ball and Jungas (41) , and the energy required for re-esterification of FFA mobilized and then taken up again in the liver and other tissues.
Lundholm showed that the calorigenic effect of epinephrine is well-correlated with the rise in serum lactate levels accompanying its administration and that infusion of lactate into rabbits induced a rise in oxygen consumption (21) (23) . The hyperglycemia accompanying epinephrine administration has also been proposed as a factor in the calorigenic response (1). Norepinephrine is much less potent than epinephrine in stimulating glycogenolysis, and at the dosages used in the present studies, there was only a minimal increase in blood glucose levels (maximal levels of 94 to 109 mg per 100 ml). Intravenous administration of glucose at rates that raised blood glucose levels to values much higher than those reached during norepinephrine infusion (over 250 mg per 100 ml) did not cause any increase in oxygen consumption. Although hyperglycemia and hyperlacticacidemia may play some role in the hypermetabolic action of epinephrine, it seems unlikely that these play an important role in the calorigenic action of norepinephrine as used in the present studies.
Another factor that might contribute to the calorigenic action of norepinephrine is an increase in cardiac work. Since cardiac metabolism only accounts for about 5 % of total body oxygen consumption in man (42) , it seems unlikely that this could be increased enough to cause the increases in rate of oxygen consumption induced by norepinephrine in these studies. Moreover, pretreatment with pronethalol did not importantly modify the changes in blood pressure and pulse rate induced by norepinephrine, whereas it did abolish the rise in oxygen consumption. When the subjects were given an intravenous dose of 75 to 100 mg of pronethalol, a betaadrenergic blocking agent, before the norepinephrine infusion, the rise in oxygen consumption and the increase in FFA levels and turnover were radically reduced or entirely abolished. The changes in blood pressure and pulse rate were essentially the same as those observed in the absence of the blocking agent.
The present findings are compatible with the hypothesis that the calorigenic action of norepinephrine is causally related to its ability to increase the rate of FFA mobilization. This may be direct, reflecting an increased rate of utilization of the FFA themselves, or indirect, reflecting utilization of triglycerides or ketone bodies formed in the liver at an increased rate as a result of more rapid hepatic uptake of FFA. In addition, the increase in oxygen consumption associated with an increased turnover of fatty acids within the adipose tissue, as previously described, may contribute to the increase in over-all metabolic rate.
